The neurological adverse events of immune check point inhibitors in the treatment of cancer
Ahmad A Toubasi, Thuraya N Al-Sayegh · 2026
Read The neurological adverse events of immune check point inhibitors in the treatment of cancer by Ahmad A Toubasi, Thuraya N Al-Sayegh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13242459.txt.
Description
Ahmad Toubasi and Thuraya Al-Sayegh reviewed clinical trials to count how often immune checkpoint inhibitors cause neurological side effects. Their systematic review and meta-analysis appeared in the Journal of Neurology in 2026. These cancer drugs free the immune system to attack tumors, but case reports have described nerve and brain problems in some patients. The authors pooled trials of previously untreated patients who received only these drugs.
Across 31 trials covering close to nine thousand patients, neurological side effects proved very rare, on the order of one case in five thousand. Using two checkpoint drugs together did not raise the rate compared with using one. Rates also looked similar across cancer types, including lung cancer and liver cancer. The authors still call for patient-level data to learn which individuals face the most risk.
Catalog record
| CREATOR | Ahmad A Toubasi, Thuraya N Al-Sayegh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |